Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

Moderna's new £150million vaccine factory in Oxfordshire is nearly finished and about to start production. The biotechnology company has invested "millions" in the plant which will create between 150 ...

(Reuters) - Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar ...

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

The United Nations Convention on Biological Diversity, or COP16, ended on Nov. 2. Several days before delegations from 177 ...

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...

Personalized medicine is changing healthcare by creating treatments specifically designed for each person. And when it comes to leading this new approach, Boston is making huge contributions. As one ...

Boston is not just a hub for history buffs and sports enthusiasts; it’s also a powerhouse of innovation that propels the ...

The company launched a major cost-cutting program and made a significant acquisition, buying cancer specialist Seagen for US$43-billion, a move which Pfizer expects to boost revenue and profits.